Search Results "#Covid"

Activities

View More Results

Mary Grace N. Tamio (Gra Sya)

on August 19 2023 at 08:37 PM Edited

Prostate cancer drug shows promise against COVID

#prostatecancer #covid

More info | ⬇️
https://cn1699.com/news/prostate-cancer-drug-shows-promise-against-covid

Prostate cancer drug shows promise against COVID | CN1699
At the outset of the COVID pandemic, men appeared to suffer higher rates of severe illness and death, leading researchers to suspect a link...
0 0 0 0 0 0 0

Comment

Like

Share
Mary Grace N. Tamio

on December 07 2022 at 09:24 PM Edited

How antibody therapy affects the breadth of COVID mRNA vaccines

#antibodytherapy #COVId #mRNA

More info | ⬇️
https://cn1699.com/news/how-antibody-therapy-affects-breadth-covid-mrna-vaccines

How antibody therapy affects the breadth of COVID mRNA vaccines | CN1699
A new study describes the unique immune response elicited in individuals who received monoclonal antibodies before taking two doses of an mRNA...
0 0 0 0 0 0 0

Comment

Like

Share
Mary Grace N. Tamio

on September 06 2022 at 06:20 PM Edited

Having high cholesterol and reduced physical stamina and being overweight are long COVID sequelae in young adults

#highcholesterol #overweight #covid #physicalstamina

More info | ⬇️
https://cn1699.com/news/having-high-cholesterol-and-reduced-physical-stamina-and-being-overweight-are-long-covid

Having high cholesterol and reduced physical stamina and being overweight are long COVID sequelae in young adults | CN1699
A new UZH study conducted with Swiss Armed Forces personnel shows that young people post COVID are likely to have increased cholesterol, a high...
0 0 0 0 0 0 0

Comment

Like

Share
Mary Grace N. Tamio

on February 09 2022 at 06:34 PM Edited

Study shows life-saving benefit of baricitinib for ventilated COVID patients

#Baricitinib #COVID19 #covid

For more information | ⬇️
https://cn1699.com/news/study-shows-life-saving-benefit-baricitinib-ventilated-covid-patients

Study shows life-saving benefit of baricitinib for ventilated COVID patients | CN1699
Critically ill COVID-19 patients on a mechanical ventilator or extracorporeal membrane oxygenation (ECMO) lived more often when randomized to...
0 0 0 0 0 0 0

Comment

Like

Share
CN1699 Social Admin

on March 19 2020 at 05:55 PM Edited

新研究发现：新冠肺炎患者发病12天内用克力芝可获益
来自澎湃新闻报道：
3月19日，《新英格兰医学杂志》（NEJM）在线发表中国团队关于使用洛匹那韦/利托那韦治疗重症新冠肺炎患者的临床试验结果，研究结论表明，在重症新冠肺炎成人住院患者中，与常规治疗相比，未观察到洛匹那韦-利托那韦（商品名：克力芝）治疗有益。但是在亚组分析中，发现患者发病12天内使用洛匹那韦/利托那韦，获益趋势更为明显，也为今后的临床试验提供了参考价值。

论文作者是包括中国工程院副院长、中国医学科学院北京协和医学院院校长王辰院士，中日友好医院副院长曹彬，武汉市金银潭医院院长张定宇等人，该研究结果经过严格的同行评议和《新英格兰医学杂志》编辑的审稿和修改，顺利发表。

该研究是在确诊新冠病毒感染的成人住院患者中开展了一项随机、对照、开放标签的试验。研究人员以1:1的比例将患者随机分组，分别接受常规治疗联合14日的每日两次洛匹那韦-利托那韦（分别为400 mg和100 mg）治疗或者单独常规治疗。主要终点是至临床状况改善的时间，其定义为从随机分组至7分等级量表评分改善2分或者出院... more

新研究发现：新冠肺炎患者发病12天内用克力芝可获益
3月19日，《新英格兰医学杂志》在线发表中国团队关于使用洛匹那韦/利托那韦治疗重症新冠肺炎患者的临床试验结果，研究结论表明，在重症新冠肺炎成人住院患者中，与常规治疗相比，未观察到洛匹那韦-利托那韦治疗有益。
0 0 0 0 0 0 0

Comment

Like

Share

Search Filters

Search Results "#Covid"

Activities